Navigation Links
FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy

The FDA has approved the drug bevacizumab (Avastin) for first time treatment of advanced lung cancer in conjunction with chemotherapy. // This comes after a large randomised study on lung cancer patients led by Dr.Alan Sandler, lung cancer specialist and director of Thoracic Oncology at Vanderbilt-Ingram Cancer Center.

Nearly 900 patients with non-small cell lung cancer (NSCLC) were tested during the trial. None of them had received any previous chemotherapy. Half were given Avastin along with standard chemotherapy drugs while the others were given chemotherapy alone. The study revealed that patients on Avastin survived an average of two months longer than the usual one year survival rate.

Though this does not sound wonderful, it is important to bear in mind that the results were based on average reactions. In some people the survival was even longer, while in others the tumours shrunk and disappeared. However there was no response in some patients.

Bevacizumab is a targeted drug, which means that it does not attack non-cancerous cells. It acts by stopping development of new blood vessels, which supply the tumours. The side effects are generally mild. However a unique and serious one is bleeding from the primary tumour, since the drug acts on the blood vessels; this has to be addressed.

Dr. Sandler is hopeful that the drug will prove path breaking and lead to better survival rates and also to more patients being cured if the disease is caught early. As NSCLC is the most common form of lung cancer in the US, this is encouraging news indeed.
SRM
'"/>




Page: 1

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...i, Feb 13 Valentine Day is assuming a new importa...ion in booming with Almost half// its population b...India has shed off old inhibitions and embraced li... Western festival of Valentine's Day despite oppos...
...een found through an animal study that Aspartame c... that drinking four to five 20-ounce bottles of di... the //cause of cancers. The study would be publi...onmental Health Perspectives, an US government-run...
...tempting to learn a new task, taking short breaks ...sy, according to a new study conducted by Massachu...Foster and Matthew Wilson, working at the Massachu...idge, found that rats' brains 'replay' their exper...
...ia in the year 2005 planned to begin stem cell res...ers passing the Proposition 71. But the legal chal...als now say that it would take spring 2007 before ..., president of the California Institute for Regene...
Other Medicine News:Health News:Valentine Day Becoming Popular In India 2Health News:Task Learning Made Simple By Taking Short Breaks 2Health News:Momentum of Stem cell research impeded by legal challenges 2
(Date:7/22/2008)...Including Lantus(R) and Apidra(R) Resulted in Sign... Diabetes, Whatever the Algorithm ... /- Results from the "Adjust to,Targe...ithm to Carbohydrate,Counting for Adjustment of Me... the American Diabetes Association,s (ADA) medical...
(Date:7/22/2008)...nd Validated by Columbia University Medical Center...MicroRNA Technology, The Test Differentiates Squ...r (NSCLC), Classifying Squamous-Cell Carcinoma of ... Specificity of 90 Percent,This is the First CLIA ...ty as Biomarkers for Accurate Diagnosis o...
(Date:7/22/2008)...Suggests That Ekkyo,s New Approach of LASH (Laser ... Scar Healing Physiology, MARSEILLES, France, Jul...wave Technology) a photomedicine company, which de... scar prevention and reduction, announced today,th... Surgery and Medicine*,reporting the results of a ...
(Date:7/21/2008)... 21 /- The SEAS (Simvastatin and Ezet...he effects of intensive,cholesterol lowering with ...zetimibe (10 mg daily) in patients with aortic ste...lockage of the aortic valve in,the heart) is a rel...rn,populations. Left untreated, it can progress to...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Cardiogenesis Reports First Quarter 2008 Results 19431 1Cardiogenesis Reports First Quarter 2008 Results 19431 2Cardiogenesis Reports First Quarter 2008 Results 19431 3Cardiogenesis Reports First Quarter 2008 Results 19431 4Cardiogenesis Reports First Quarter 2008 Results 19431 5Cardiogenesis Reports First Quarter 2008 Results 19431 6Discover Talent Management Best Practices June 4 6 Registration Ends Friday 19429 1Discover Talent Management Best Practices June 4 6 Registration Ends Friday 19429 2Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 1Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 2Human Genome Sciences Names Kevin P McRaith Vice President Hepatology Franchise 5426 3AEterna Zentaris to Present at Upcoming Rodman 26 Renshaw Global Healthcare Conference and AUA Annual Meeting 5424 1AEterna Zentaris to Present at Upcoming Rodman 26 Renshaw Global Healthcare Conference and AUA Annual Meeting 5424 2
...RE)--Apr 16, 2007 - Antigenics Inc.,(NASDAQ: AGEN)...ata,from a Phase 1/2 investigator-sponsored trial ...cophage(R) (vitespen) in,recurrent, high-grade gli...ociation of Neurological Surgeons (AANS; abstract,...onducted at the,Brain Tumor Research Center at the...
...ctive Anti-VEGF Antibodies Inhibited Tumor Growth ...er Model -, , - Peregrine,s Antibodies that Select...Have Advantages over Non-Selective Approaches - , ...ly Human,Antibody Support , Advancing Peregrine,s ...ANGELES and TUSTIN, Calif., April 16, 2007,/PRNews...
Other Medicine Technology:Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 2Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 3Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 2Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 3Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 4Data Presented at AACR Meeting Shows Peregrine's Selective,Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical,Cancer Models 5
...the most comprehensive family of lightweight stand...incision, Glaucoma filtration, and Vitreoretinal u... with minimal tissue trauma and minimal peripheral...ilable in 18, 20, and 20-23Ga tapered designs. Add...
...the most comprehensive family of lightweight stand...incision, Glaucoma filtration, and Vitreoretinal u... with minimal tissue trauma and minimal peripheral...ilable in 18, 20, and 20-23Ga tapered designs. Add...
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek now makes them available to you! Only holders of the coveted Meisterbrief certificate, which r
Centuries of German Craftsmanship have produced the finest surgical instrumentation in the world. Ocutek now makes them available to you! Only holders of the coveted Meisterbrief certificate, which r
Medicine Products: